Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers

Conditions:   Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Non Small Cell Lung Cancer;   Hepatocellular Cancer;   Colorectal Cancer;   Gastric Adenocarcinoma;   Melanoma;   Advanced Cancer
Intervention:   Drug: C188-9
Sponsors:   StemMed, Ltd., USA;   M.D. Anderson Cancer Center
Not yet recruiting - verified June 2017

http://ift.tt/2sYSIn0